Jun 10, 2022 / 04:15PM GMT
Sean Tan - Jefferies LLC - Analyst
Welcome to our session. My name is [Sean Tan], I'm an associate at Jefferies working with Senior analysts at [HP]. Today I'm very pleased to introduce Cameron Durrant, the Chairman and CEO of Humanigen, to introduce to us the story of Humanigen. So we will have a presentation first from Cameron and then a short Q&A session. Cameron, please.
Cameron Durrant - Humanigen, Inc. - Chairman & CEO
Thank you very much indeed, Sean, and thank you to Jefferies for inviting Humanigen to the conference today. And thank all of you for being in the room with me today. I am going to show you our FLS and then dive into the focus of our discussion today, which will be lenzilumab.
Lenzilumab is a monoclonal antibody that we've developed through a technology which we call Humaneering. Humaneering conveys certain benefits, including the highest binding affinity in the category; and lenzilumab binds GM-CSF, granulocyte-macrophage colony-stimulating factor. It also has the slowest off-rate in its class. And those and a number of
Humanigen Inc at Jefferies Healthcare Conference Transcript
Feb 13, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers